share_log

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $40

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $40

坎托·菲茨杰拉德维持对Abeona Therapeutics的增持,将目标股价提高至40美元
Benzinga Real-time News ·  2022/11/08 11:32

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $22 to $40.

坎托·菲茨杰拉德分析师克里斯汀·克鲁斯卡维持Abeona Therapeutics(纳斯达克股票代码:ABEO)增持 “增持”,并将目标股价从22美元上调至40美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发